HR-8596-119
Referred to the Committee on Agriculture, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsored by Mark Alford (R-MO)
What it does
This bill would amend the Federal Meat Inspection Act, the Poultry Products Inspection Act, and the Federal Food, Drug, and Cosmetic Act to require mandatory labeling for two categories of products: (1) "cell-cultivated protein products" — foods grown from animal cells outside a live animal — must display the words "cell-cultivated" prominently on the label and include a disclaimer that the product is not conventional meat; and (2) "plant-based alternative protein products" — plant-derived foods designed to mimic meat or poultry — must be labeled as such and state they contain no naturally produced meat. The bill would also direct USDA and FDA to revise their existing regulatory agreement within 90 days and develop common standards of identity for both product categories within 180 days.
Who benefits
Conventional meat and poultry producers (cattle, hog, and poultry farmers) who argue they compete against products that may be mistaken for conventional meat. Consumers who prefer conventional meat and want clear differentiation at point of sale. Rural agricultural communities economically dependent on livestock production. Retailers who would have clearer compliance standards. Consumers with dietary, religious, or cultural preferences tied to how food is produced (e.g., halal, kosher, or farm-to-table consumers) who may want to distinguish production methods.
Who is hurt
Cell-cultivated protein companies (e.g., startups producing lab-grown chicken or beef) that may face consumer resistance due to required disclaimers. Plant-based meat companies (e.g., producers of plant-based burgers and sausages) that would need to revise packaging and may face reduced consumer appeal. Investors in alternative protein industries who could see market value affected. Consumers who prefer alternative proteins and may face higher prices if compliance costs are passed on. Smaller alternative protein producers with fewer resources to absorb labeling redesign costs.
Supporters argue
Supporters argue that consumers have a fundamental right to know what they are buying, and that current labeling practices allow cell-cultivated and plant-based products to be marketed under names like "chicken" or "beef" in ways that may mislead shoppers. They contend that conventional livestock producers — an industry supporting over 800,000 U.S. farms — face unfair competition when alternative products are not clearly distinguished at the point of sale. They further argue that establishing clear standards of identity now, before the alternative protein market scales significantly, prevents consumer confusion and creates a stable regulatory framework for all producers.
Opponents argue
Opponents argue that existing FDA and USDA misbranding rules already prohibit deceptive labeling, making additional mandates redundant and potentially designed to stigmatize emerging food technologies rather than inform consumers. They contend that requiring prominent disclaimers — such as "not derived from naturally produced meat" — goes beyond neutral disclosure and functions as a warning label that could unfairly disadvantage products that regulators have already deemed safe. They further argue that the 90- and 180-day deadlines for revising interagency agreements and developing standards of identity are unrealistically short for complex rulemaking, potentially producing poorly designed regulations.
Constitutional context
Congress has broad authority to regulate food labeling under the Commerce Clause (Art. I, §8, cl. 3), as food products move extensively in interstate commerce — well within the aggregation principle established in Wickard v. Filburn (1942). The bill delegates rulemaking authority to USDA and FDA; post-Loper Bright v. Raimondo (2024), courts will independently review whether those agencies' implementing regulations stay within the statutory boundaries Congress sets here, rather than deferring to agency interpretations.
Checks and balances
Congress gains authority by directly writing labeling mandates into statute; USDA and FDA implement standards of identity and interagency agreements, subject to independent judicial review of agency rules under Loper Bright (2024).
Historical precedent
Several states, including Missouri (2018) and Mississippi (2019), enacted laws restricting how alternative protein products can be labeled, with some facing First Amendment commercial speech challenges in federal court, though no Supreme Court ruling has resolved the question at the federal level.